Fresenius Medical Care to Present Extensive Research at the American Society of Nephrology’s Kidney Week 2014 Conference
November 11 2014 - 8:00AM
Business Wire
Presentation Highlights Include Programs to
Reduce Hospitalizations and Improve Health Outcomes of Dialysis
Patients
Fresenius Medical Care North America (FMCNA), the continent’s
leading provider of kidney care products and services, announced
today that it will be presenting a broad array of clinical research
at this year’s American Society of Nephrology (ASN) Kidney Week
2014 conference.
In all, ASN selected 43 research abstracts from FMCNA authors to
be presented during the conference, which is scheduled for Nov.
11-16 in Philadelphia, and expected to attract more than 13,000
leading kidney professionals.
This year’s FMCNA research presentations at the conference
represent one of the most significant portfolios of peer-reviewed
research accepted from a single organization. The authors’
collective efforts demonstrate FMCNA’s continued commitment to
advancing the scientific and clinical understanding of kidney
disease and improving the care of kidney patients. Key topics
addressed by the company’s research initiatives include:
- Decreasing hospital admissions and
readmissions
- Strategies for improving the prognosis
for CKD patients as they transition to become incident dialysis
patients
- Reducing the problem of fluid overload
in dialysis patients
These initiatives are already resulting in fewer
hospitalizations, better patient outcomes and treatment cost
savings.
“Fresenius Medical Care is dedicated to improving the lives of
people with kidney disease and other chronic illnesses, and our
ability to deliver on this commitment starts with clinical
research,” said Franklin W. Maddux, M.D., FMCNA’s chief medical
officer and executive vice president for clinical and scientific
affairs. “We are hopeful that the research we present at ASN will
provide meaningful guidance for providers and caregivers throughout
the health care industry.”
Seven FMCNA scientists and clinicians will present their work
orally during this year’s ASN conference. Highlights of those
research presentations include:
- Low blood pressure’s effect on
incident patient outcomes; Lower systolic blood pressures are
consistently associated with poorer outcomes in the early stages of
incident hemodialysis patients’ treatment. This oral presentation
(TH-OR138) will be given by Dugan W. Maddux, M.D., vice president
of chronic kidney disease initiatives at FMCNA.
- Body size and gender risks in
ultrafiltration; How body size and gender-dependent differences
in mortality risks are associated with ultrafiltration rates. This
oral presentation (TH-OR079) will be given by John W. Larkin,
clinical research coordinator, Frenova Renal Research.
- Improving communications in dialysis
care; Improved results and user satisfaction are demonstrated
in trials of the new Dialysis Link™ system for transferring patient
information between dialysis clinics and hospitals in the Right
TraC™ Transitions of Care program. This oral presentation
(FR-PO1097) will be given by Rebecca Wingard, RN, MSN, vice
president, quality initiatives, FMCNA.
- Effects of low pre-dialysis serum
sodium on frequent hemodialysis; How low pre-dialysis serum
sodium modifies the effect of hemodialysis frequency on left
ventricular mass in the Frequent Hemodialysis Network trial. This
oral presentation (TH-OR081) will be given by Jochen Raimann, M.D.,
Ph.D., research scientist at FMCNA’s Renal Research Institute.
- Reducing fluid overload-related
hospitalizations; An innovative FMCNA program to reduce fluid
overload in hemodialysis patients is reducing hospitalizations and
missed treatments. This oral presentation (TH-OR142) will be given
by Stephanie Johnstone, LCSW, director of social work in disease
management at FMCNA.
Fresenius Medical Care contributes research to ASN each year to
further the advancement of kidney care quality and improve patient
outcomes.
About Fresenius Medical Care North AmericaThrough its
leading network of more than 2,150 dialysis facilities in North
America and vascular access centers, labs, pharmacy, inpatient
physicians, urgent care centers, affiliated hospitals and
nephrology practices, Fresenius Medical Care provides renal
services to hundreds of thousands of people throughout the United
States, Mexico and Canada. It is also the continent's top producer
of dialysis equipment, dialyzers and related disposable products
and a major supplier of renal pharmaceuticals. For more information
about the company, visit www.fmcna.com; for information about
patient services, visit www.ultracare-dialysis.com.
About the American Society of NephrologyFounded in 1966,
the American Society of Nephrology (ASN) is the world’s largest
professional society devoted to the study of kidney disease. With
11,000 physician and scientist members, ASN leads the fight against
kidney disease by educating health professionals, sharing new
knowledge, advancing research, and advocating the highest quality
care for patients. ASN also informs policymakers about issues of
importance to kidney doctors and their patients. ASN funds
research, and through its world-renowned meetings and first-class
publications, disseminates information and educational tools that
empower physicians. For more information about the society, visit
www.asn-online.org/.
Media Contact:Fresenius Medical Care North AmericaJon
Stone, 781-699-9704Cell: 781-392-4680Jonathan.d.stone@fmc-na.com
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2024 to May 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From May 2023 to May 2024